CapioCyte CTC System
Cancer Diagnostics & Monitoring
Research & DevelopmentActive
Key Facts
Indication
Cancer Diagnostics & Monitoring
Phase
Research & Development
Status
Active
Company
About Capio Biosciences
Capio Biosciences is a private, pre-revenue diagnostics company founded in 2019 and headquartered in Cambridge, Massachusetts, USA. The company is developing the CapioCyte platform, which utilizes a novel combination of biomimetic cell rolling and adhesion to achieve significantly greater sensitivity (reportedly 10-100x) in capturing CTCs compared to existing technologies. While still in the research and development stage, early clinical data is promising, positioning CapioCyte as a potential future tool for cancer research and clinical diagnostics. The company has secured non-dilutive grant funding and established a subsidiary in Korea.
View full company profile